- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02875353
Blood Flow Monitoring to Prevent Post-Polypectomy Induced Ulcer Bleeding
Blood Flow Monitoring to Prevent Post-Polypectomy Induced Ulcer Bleeding.
Study Overview
Status
Intervention / Treatment
Detailed Description
VA Central Office recently opened back research study after suspension from March to Sept 2020 with COVID 19
Severe delayed post-polypectomy induced ulcer (PPIU) bleeding has become a much more common problem with the increased numbers of colonoscopies being performed and with more patients taking anti-coagulants or anti-platelet drugs. Current medical guidelines may reduce bleeding during polypectomy, but are not effective for prevention of delayed bleeding. Empiric closure of PPIU's with clips is not effective because ulcers > 15 mm cannot be closed, does not treat the underlying artery in the ulcer base, and when the clips often fall off within 7 the underlying artery is exposed. As preliminary results, the investigators studied delayed PPIU bleeds and their prevention, used a Doppler endoscopic probe (DEP) to localize arteries in PPIU's, reported the prevalence which rises significantly as ulcer size increases, and successfully obliterated blood flow with focal treatment. These studies form the basis for this new RCT. The primary specific aim is to perform a RCT to compare rates of delayed hemorrhage after DEP detection of arterial blood flow and focal treatment in PPIU's (treatment arm) with standard treatment using medical guidelines alone (controls) for prevention of delayed bleeding in high risk patients (on anti-coagulants or anti-platelet drugs or with large ulcers) after snare resection of benign colon polyps. Secondary specific aims are to evaluate the natural history and risk factors for delayed PPIU bleeding using univariate and multivariable analyses. This is a RCT performed by the CURE Hemostasis Research Group for high risk patients - those with PPIU's 15 mm in size or greater but not on drugs associated with bleeding; or patients who require anti-coagulants or anti-platelet drugs for treatment of co-morbid conditions and have PPIU's 10 mm or larger. Outpatients, scheduled for screening or surveillance colonoscopies, who give written informed consent and meet entry criteria will be randomized to control/no DEP (medical treatment without PPIU closure) or DEP (as a guide to arterial blood flow detection and focal obliteration of it with hemoclips and/or low power multipolar electrocautery [MPEC] probe). Patients will be prospectively followed at 7, 14, and 30 days for bleeding, complications, or unscheduled visits for healthcare after polypectomies.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Dennis M Jensen, MD
- Phone Number: (310) 268-3569
- Email: dennis.jensen@va.gov
Study Locations
-
-
California
-
Downey, California, United States, 90242
- Recruiting
- Kaiser Permanente-Downey Medical Center
-
Contact:
- Kevin T Kao
- Phone Number: 562-657-4441
- Email: kevin.T.Kao@kp.org
-
Contact:
- Gareth S Dulai
- Phone Number: 5626574242
- Email: Gareth.S.Dulai@kp.org
-
Los Angeles, California, United States, 90095
- Recruiting
- University of California, Los Angeles, Ronald Reagan Medical Center
-
Contact:
- Dennis M Jensen, MD
- Phone Number: 310-268-3569
- Email: dennis.jensen@va.gov
-
West Los Angeles, California, United States, 90073-1003
- Recruiting
- VA Greater Los Angeles Healthcare System, West Los Angeles, CA
-
Principal Investigator:
- Dennis M. Jensen, MD
-
Contact:
- Dennis M Jensen, MD
- Phone Number: 310-268-3569
- Email: dennis.jensen@va.gov
-
Contact:
- Kwanmanus N Suvanamas, BS
- Phone Number: 43324 (310) 478-3711
- Email: Kwanmanus.Suvanamas@va.gov
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Ambulatory patients, 35 years old or more and who are having:
- elective, outpatient screening
- surveillance colonoscopy for colon cancer or polyps
- or being evaluated for abdominal pain or change in bowel habits ---or have a large polyp needing removal by EMR or ESD
Clinically the patient has to have a medical indication and recommendation by their primary care physician (PCP) or specialist to take:
- daily anti-coagulants (Warfarin, low-molecular-weight heparin [LMWH] or a newer agent)
- or an anti-platelet drug (aspirin as 81 mg or more, Clopidogrel, or newer agents) for PPIU's 10-14mm
- or if not on one of these drugs, they must have a PPIU 15 mm
On colonoscopy, they are required to have:
- benign appearing polyps and for 1 or more PPIU to be 10 mm in size (for the anti-coagulant or anti-platelet groups)
- or 15 mm or larger for the PPIU group who do not have to be (but may be) on these drugs that can induce bleeding
- In the case of bleeding from the PPIU during polypectomy, hemorrhage must be completely controlled
Exclusion Criteria:
- Inability or unwillingness to give written informed consent or to return to the investigators' medical centers for follow-up (FU) in the next 30 days, in case of delayed bleeding or other complications
Intrinsic bleeding disorder with a history of recurrent bleeding either after:
- surgeries
- angiography
- or other invasive procedures
- Significantly abnormal coagulation tests related to co-morbid liver, hematologic, or infectious disorders and not anti-coagulant drugs, with platelet count < 100,000; international normalized ratio (INR) > 1.5; or partial thromboplastin time (PTT) more than 1.5 times normal
- Inflammatory bowel disease
- Infectious colitis
- Idiopathic colitis with a history of recurrent rectal bleeding
Recurrent rectal bleeding from another chronic colorectal condition such as:
- colonic angiomas
- radiation colitis
- proctitis
- or internal hemorrhoids
- A sessile polyp that can not be raised up by saline injection or Endoscopic mucosal resection (EMR) techniques nor completely removed by snare polypectomy either en block or in pieces and there is a suspicion about possible malignancy by the colonoscopist.
- Recently colonoscopy (within less than 3 years) unless the patient is referred for a large or multiple polyps (on more recent colonoscopy) and colonoscopic removal in the investigators' referral centers
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Standard endoscopy (not experimental)
For Standard treatment group, the Doppler probe will not be used, nor will hemoclip closure of post-polypectomy ulcers be attempted.
Standard published guidelines will be followed for management of blood thinners (anti-coagulants) and/or aspirin like drugs (anti-platelet drugs) before and after the colonoscopic polypectomies.
This is the standard of care at the investigators' medical centers and part of written instructions that are given to the participants and their referring physicians during the scheduling process and prior to their preparation for screening or surveillance outpatient colonoscopies.
|
A colon length catheter (probe).
|
Experimental: Doppler treatment (experimental)
A colon length catheter (probe) will be used to check the non-bleeding post-polypectomy ulcer with shallow and medium depth Doppler probe settings (< 4 mm deep) for arterial blood flow.
If arterial flow is found, treatment through the colonoscope (either hemoclipping or multipolar electrocoagulation probe) will be used to stop the arterial flow.
This will be confirmed by rechecking with Doppler probe after endoscopic treatment.
Tatoos (Spot method) will be placed on two sides of the ulcer so treated.
|
A colon length catheter (probe).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of participants with delayed Post-Polypectomy Induced Ulcer (PPIU) bleeds.
Time Frame: Outcome measure will be assessed at 30 days after participants are enrolled.
|
We will compare the proportion of participants with PPIU bleeding by 30 days follow up in Doppler endoscopic probe (DEP) versus standard treatment.
The p value for testing this hypothesis will be computed using Fisher's exact test.
The corresponding 95% confidence bounds for the true difference will also be reported.
|
Outcome measure will be assessed at 30 days after participants are enrolled.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of participants hospitalized.
Time Frame: Outcome measure will be assessed at 30 days after participants are enrolled.
|
We will compare the proportion of participants hospitalized for PPIU bleeds or other complications at 30 days, the number of participants in DEP group and standard group overall.
Fisher's exact test will be used to compare the proportion hospitalized for PPIU bleeding by 30 days in DEP versus standard.
|
Outcome measure will be assessed at 30 days after participants are enrolled.
|
The total number of hospitalized days.
Time Frame: Outcome measure will be assessed at 30 days after participants are enrolled.
|
We will determine if number of hospitalized days follows a count distribution such as the Poisson or Negative Binomial distribution or if the log total hospital days follows a normal or other parametric distribution.
We will therefore use the appropriate count model, t test or non parametric test (Wilcoxon rank sum) to compare the number of days hospitalized distribution in DEP versus standard as well as report the corresponding descriptive statistics (n, range, quartiles, median, mean, SD, frequencies) and histogram.
|
Outcome measure will be assessed at 30 days after participants are enrolled.
|
The proportion of participants with rectal bleeding reported to us but not severe enough to be hospitalized
Time Frame: Outcome measure will be assessed up to 30 days after enrollment
|
Comparison of proportion of participants with rectal bleeding reported to us but not severe enough to be hospitalized.
Fisher's exact test will be used to compare the proportion with this type of rectal bleeding after polypectomy up to 30 days after enrollment in the DEP versus standard treatment groups.
|
Outcome measure will be assessed up to 30 days after enrollment
|
Collaborators and Investigators
Investigators
- Principal Investigator: Dennis M. Jensen, MD, VA Greater Los Angeles Healthcare System, West Los Angeles, CA
Publications and helpful links
General Publications
- Hui AJ, Wong RM, Ching JY, Hung LC, Chung SC, Sung JJ. Risk of colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents: analysis of 1657 cases. Gastrointest Endosc. 2004 Jan;59(1):44-8. doi: 10.1016/s0016-5107(03)02307-1.
- Liaquat H, Rohn E, Rex DK. Prophylactic clip closure reduced the risk of delayed postpolypectomy hemorrhage: experience in 277 clipped large sessile or flat colorectal lesions and 247 control lesions. Gastrointest Endosc. 2013 Mar;77(3):401-7. doi: 10.1016/j.gie.2012.10.024. Epub 2013 Jan 11.
- Zuckerman MJ, Hirota WK, Adler DG, Davila RE, Jacobson BC, Leighton JA, Qureshi WA, Rajan E, Hambrick RD, Fanelli RD, Baron TH, Faigel DO; Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy. ASGE guideline: the management of low-molecular-weight heparin and nonaspirin antiplatelet agents for endoscopic procedures. Gastrointest Endosc. 2005 Feb;61(2):189-94. doi: 10.1016/s0016-5107(04)02392-2.
- Baron TH, Kamath PS, McBane RD. New anticoagulant and antiplatelet agents: a primer for the gastroenterologist. Clin Gastroenterol Hepatol. 2014 Feb;12(2):187-95. doi: 10.1016/j.cgh.2013.05.020. Epub 2013 Jun 2.
- Wong RC. Endoscopic Doppler US probe for acute peptic ulcer hemorrhage. Gastrointest Endosc. 2004 Nov;60(5):804-12. doi: 10.1016/s0016-5107(04)02046-2. No abstract available.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLNB-01-15F
- CX-001403-01 (Other Grant/Funding Number: Veterans Affairs Clinical Merit Review Grant)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Delayed Post-Polypectomy Induced Ulcer Hemorrhage
-
Indiana UniversityCompletedProcedural Bleeding | Delayed Bleeding | Post-Polypectomy Syndrome | Post Procedural ComplicationUnited States
-
VA Office of Research and DevelopmentCompletedPolypectomy | Post-polypectomy Bleeding | Elective ColonoscopyUnited States
-
Chinese University of Hong KongRecruitingPost Polypectomy BleedingHong Kong
-
Renmin Hospital of Wuhan UniversityNot yet recruitingColorectal Polyp | Post-polypectomy BleedingChina
-
Ningbo No. 1 HospitalCompletedBowel Preparation | Post-polypectomy Bleeding | Urgent ColonoscopyChina
-
Hadassah Medical OrganizationRambam Health Care Campus; Carmel Medical Center; Soroka University Medical Center and other collaboratorsUnknownGastrointestinal Hemorrhage | Post Polypectomy Bleeding in Anticoagulated Patients
-
Incheon St.Mary's HospitalSeoul St. Mary's Hospital; Keimyung University Dongsan Medical Center; Soonchunhyang... and other collaboratorsCompletedPost Polypectomy BleedingKorea, Republic of
-
National University of MalaysiaCompletedPost Partum Hemorrhage | Mode of Delivery | Delivery Delayed | Uterine Hyperstimulation
-
Western Sydney Local Health DistrictCompletedEndoscopic Mucosal Resection | Delayed Bleeding Post EMR | Large Laterally Spreading Lesion in the ColonAustralia
-
University of MichiganNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedPeptic Ulcer Hemorrhage | Upper Gastrointestinal Bleeding | Anticoagulant-induced BleedingUnited States
Clinical Trials on Doppler Endoscopic Probe
-
VA Office of Research and DevelopmentKaiser Permanente Bellflower Medical Offices; UCLA Ronald Reagan Medical CenterCompletedEndoscopy | UGI Bleeding | Ulcer or Variceal Hemorrhage | Stigmata of Recent Hemorrhage | Randomized Controlled TrialsUnited States
-
Chinese University of Hong KongUniversity Hospitals Cleveland Medical CenterTerminated
-
University of California, San DiegoCompletedStroke | Brain Diseases | Brain Injuries | Vasospasm | Medical Device ComplicationUnited States
-
University Hospital Plymouth NHS TrustCompletedRenal Artery Complications | Renal Vein ThrombosisUnited Kingdom
-
Weill Medical College of Cornell UniversityEMcision LimitedTerminatedPancreatic Cancer | CholangiocarcinomaUnited States
-
Ochsner Health SystemUnknown
-
University of VirginiaUnknown
-
Helse Nord-Trøndelag HFNorwegian University of Science and Technology; St. Olavs HospitalCompletedStroke | Transient Ischemic Attack | Ischemic Attack, Transient | Cerebrovascular Accident | Cerebrovascular ApoplexyNorway
-
Samsun Education and Research HospitalCompleted
-
University of FloridaFlorida Probe CorporationCompletedPeriodontitis | Diagnoses DiseaseUnited States